Literature DB >> 8216364

Effects of morphine and its metabolites on opiate receptor binding, cAMP formation and [3H]noradrenaline release from SH-SY5Y cells.

D G Lambert1, R Atcheson, R A Hirst, D J Rowbotham.   

Abstract

Opiate receptor occupation leads to a variety of intracellular events including inhibition of adenylyl cyclase and cAMP formation. We have examined the opiate binding characteristics, effects on cAMP formation and [3H]noradrenaline release of morphine, morphine-6 (M6G) and -3 (M3G)-glucuronides, and fentanyl in SH-SY5Y human neuroblastoma cells. M6G and M3G are the major metabolites of morphine formed in vivo whose cellular action remains to be fully elucidated. In binding experiments morphine (affinity, K50 = 96 nM) and fentanyl (K50 = 99 nM) were more potent than M6G (K50 = 393 nM), while M3G was inactive. However, for cAMP inhibition morphine (half maximum inhibition, IC50 = 193 nM) and M6G (IC50 = 113 nM) were roughly equipotent, with fentanyl (IC50 = 27 nM) being more potent and producing a greater maximum inhibition (56%). M3G was inactive. These in vitro data are in general agreement with the in vivo effects of these glucuronides. Moreover, all of the opiates tested failed to inhibit K(+)-evoked release of [3H]noradrenaline. Whilst these data do not support a role for cAMP in neurotransmitter release, alterations in cAMP formation may still have a role to play in the mechanism of analgesia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216364     DOI: 10.1016/0006-2952(93)90462-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus.

Authors:  P B Osborne; B Chieng; M J Christie
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor.

Authors:  C Harrison; D J Rowbotham; D K Grandy; D G Lambert
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

4.  The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant mu-opioid receptors and SH-SY5Y cells.

Authors:  C Harrison; S McNulty; D Smart; D J Rowbotham; D K Grandy; L A Devi; D G Lambert
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  Studies on the mechanism of [3H]-noradrenaline release from SH-SY5Y cells: the role of Ca2+ and cyclic AMP.

Authors:  R Atcheson; D G Lambert; R A Hirst; D J Rowbotham
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

6.  Mu-opioids activate phospholipase C in SH-SY5Y human neuroblastoma cells via calcium-channel opening.

Authors:  D Smart; G Smith; D G Lambert
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

7.  The effects of morphine on tissue structure of the growth plate in male rats.

Authors:  Massood Ezzatabadipour; Masoud Majidi; Reza Malekpour-Afshar; Seyed Hasan Eftekharvaghefi; Seyed Noureddin Nematollahi-Mahani
Journal:  Iran J Basic Med Sci       Date:  2011-11       Impact factor: 2.699

8.  Differential Regulation of 6- and 7-Transmembrane Helix Variants of μ-Opioid Receptor in Response to Morphine Stimulation.

Authors:  Marino Convertino; Alexander Samoshkin; Chi T Viet; Josee Gauthier; Steven P Li Fraine; Reza Sharif-Naeini; Brian L Schmidt; William Maixner; Luda Diatchenko; Nikolay V Dokholyan
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

Review 9.  Opioids in COVID-19: Two Sides of a Coin.

Authors:  Camila Vantini Capasso Palamim; Matheus Negri Boschiero; Aléthea Guimarães Faria; Felipe Eduardo Valencise; Fernando Augusto Lima Marson
Journal:  Front Pharmacol       Date:  2022-01-06       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.